drugset / Trial / NCT02697383
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Phase 1
Completed
14 enrolled
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.
Timeline
- Start
- 2016-02
- Primary completion
- 2024-05-08
- Completion
- 2024-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Ixazomib | Unknown | 4 mg | — |